Blockchain could help ensure clinical trial integrity
22 February 2019 | By Nikki Withers (European Pharmaceutical Review)
US researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data using blockchain...
List view / Grid view
Clinical Trials
Whitepaper: Analytical criteria in bacterial endotoxin testing using LAL and rFC
21 February 2019 | By Hyglos-bioMerieux
This article covers the analytical criteria that apply to Bacterial Endotoxin Testing (BET) using Limulus Amebocyte Lysate (LAL) or recombinant Horseshoe crab Factor C (rFC) for the bioactivity determination of endotoxin in aqueous solutions, such as pharmaceuticals and medical device extracts. It explains the importance of these criteria for accurate…
‘Smart drug’ shows promise for metastatic triple-negative breast cancer
21 February 2019 | By European Pharmaceutical Review
A study has shown that a 'smart drug' that delivers a toxic payload directly to tumour cells could be a possible treatment for breast cancer...
Structural barriers biggest reason for low participation in clinical trials
20 February 2019 | By European Pharmaceutical Review
A study has shown how structural barriers are one of the main reasons why clinical trials often do not meet their enrolment targets...
Inadequate FDA oversight concerning fentanyl prescriptions
19 February 2019 | By European Pharmaceutical Review
A study has found that the FDA failed to design and implement an effective monitoring program for Transmucosal Immediate-Release Fentanyls...
Biotech firm awarded for approach to drug development
18 February 2019 | By European Pharmaceutical Review
A UK based biotech firm has been awarded a grant to develop a treatment for osteoarthritis, after promising results from a Phase I trial...
Phase III combination trial improves survival in men with metastatic prostate cancer
15 February 2019 | By European Pharmaceutical Review
A Phase III clinical trial has shown that metastatic prostate cancer improved through the use of a combination therapy with enzalutamide...
No association between antiepileptic drug use and dementia
15 February 2019 | By Iqra Farooq (European Pharmaceutical Review)
Antiepileptic drugs have been found to have no association with dementia, with researchers looking at the data of over 50,000 patients...
SMC accepts restricted use of rivaroxaban for CAD
13 February 2019 | By Iqra Farooq (European Pharmaceutical Review)
The SMC has approved a drug, called rivaroxaban, that targets Factor Xa to treat those with coronary artery disease (CAD)...
Phase III clinical trial for treatment of dry eye syndrome
12 February 2019 | By Iqra Farooq (European Pharmaceutical Review)
A Phase III trial looks to treat dry eye syndrome using a sterile, preservative-free eye drop formulation that has thymosin beta 4 as its active ingredient...
Health Canada issues NOC/c for oral myeloid leukaemia therapy
12 February 2019 | By European Pharmaceutical Review
Health Canada has issued a Notice of Compliance with conditions for the first oral drug for acute myeloid leukaemia, a rapidly progressing condition...
NICE and Canadian Agency collaborate to offer parallel scientific advice
8 February 2019 | By Iqra Farooq (European Pharmaceutical Review)
NICE in the UK and its counterpart - the Canadian Agency for Drugs and Technology in Health have collaborated to offer parallel scientific advice...
Omadacycline similar to commonly-used antibiotics for treating pneumonia, skin infections
7 February 2019 | By Nikki Withers (European Pharmaceutical Review)
Findings of two phase III, double-blind, randomised clinical trials comparing omadacycline with standard antibiotics have been published in the New England Journal of Medicine
Combination antiplatelet therapy reduces risk of recurrent stroke
7 February 2019 | By European Pharmaceutical Review
A combination therapy using the blood thinner cilostazol, along with either aspirin or clopidogrel, was shown to decrease the risk of stroke recurrence...
FDA approval for Cablivi to treat rare clotting disorder
7 February 2019 | By European Pharmaceutical Review
The FDA has approved the first specific therapy for the rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP)...
Follow: